NKGen Biotech Inc. (OTC: NKGN) announced it will present data from Phase 1 clinical studies of its troculeucel therapy for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE